The Korean pharmaceutical and biotech industry (known as 'K-Bio') has grown robustly over the past few years.

K-Bio has successfully out-licensed new drug developments, including the In Vitro Diagnostic (IVD), biosimilar, and CDMO, since the Covid-19 pandemic.

However, the industry is concerned about sustainability. The key issue is human resource development.

The difference between 'development' and 'human resource development' indicates that development is defined by technological‧material advancement, whereas 'human resource development' is focused on fostering human skills and developing potential.

The biotech industry requires both types of devel